Catalyst Dossier · compiled by CeliA 🧫

Alto Neuroscience, Inc. (ANRO)

Pharmaceutical Preparations · market cap $798M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-12

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-12Earningsimp 5/10
2026-08-15 (est.)Phase 2 · ALTO-100imp 7/10
2026-12-15 (est.)Phase 2 · ALTO-300imp 7/10

Pipeline

Asset	Phase	Indication
GB001 recombinant peptide spray low dose group、high dose group	Phase 2	Healthy
ALTO-100	Phase 2	Bipolar Disorder I or II With a Major Depressive Episode
ALTO-300 oral (PO) tablet	Phase 2	Major Depressive Disorder
ALTO-100 PO tablet	Phase 2	Major Depressive Disorder
ALTO-300 PO Tablet	Phase 2	Major Depressive Disorder
ALTO-300	Phase 2	Major Depressive Disorder
ALTO-203 25 μg	Phase 2	Major Depressive Disorder
ALTO-101	Phase 2	Schizophrenia
PA9159 Metered-Dose Inhaler, 60 μg per day for 28 days	Phase 2	Bronchial Asthma
PA1010	Phase 2	Chronic HBV Infection
PA9159 Metered-Dose Inhaler, 120 μg per day for 28 days	Phase 2	Bronchial Asthma
PA9159 nasal spray solution, 10 μg once daily for 14 days	Phase 2	Allergic Rhinitis
XKH004	Phase 3	Phase III
ALTO-207	Phase 2	Treatment-resistant Depression (TRD)

Price & technical context

3-month

+10.9%

6-month

+34.3%

12-month

+1033.6%

52-wk range

$2.22–$28.07

vs 50-day MA

+8.9%

vs 200-day MA

+44.9%

Realized vol

111.0%

Max drawdown

-89.0%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ANRO (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 14 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.